Literature DB >> 31376591

Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry.

Ryan C Schofield1, Heather J Landau2, Sergio A Giralt2, Gunjan L Shah2, Michael Scordo2, Andrew Lin3, Elaine Zanutto4, Lakshmi V Ramanathan1, Melissa S Pessin1, Dean C Carlow5.   

Abstract

Busulfan and melphalan are cytotoxic DNA alkylating agents that are used in many hematopoietic stem cell transplantation (HCT) conditioning regimens. We report the development of an assay using turbulent flow liquid chromatography (TFLC) and tandem mass spectrometry to simultaneously measure the concentration of busulfan (Bu) and melphalan (Mel) in human plasma. The method involves precipitating proteins in the plasma specimen with an organic solvent containing deuterated internal standards of both compounds. Following centrifugation, an aliquot of the supernatant was injected into the TFLC mass spectrometry system operated in the positive ion mode. The analytical measurement range for both compounds was 10-5000 ng/mL, and with validated dilutions the reportable range was extended to 25,000 ng/mL. Intra-day and inter-day (n = 20 day) precision studies showed a coefficient of variation (CV) of <7% at several concentrations across the measurement range. To determine accuracy recovery studies were performed at several concentrations spanning the measurement range. Recoveries for both compounds were between 98 and 103%. Additionally, busulfan was compared with an existing assay and showed excellent correlation. Experiments were conducted to rule out matrix effects, carryover and interference from endogenous substances. The validated clinically reportable range (CRR) and assay precision will allow this assay to be used clinically to monitor and adjust Mel and Bu levels to ensure better therapeutic outcomes and also to support clinical trials aimed at better defining therapeutic ranges.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Busulfan; Melphalan; Pharmacokinetic studies; Tandem mass spectrometry; Turbulent flow liquid chromatography

Year:  2019        PMID: 31376591      PMCID: PMC6692901          DOI: 10.1016/j.jchromb.2019.121711

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.

Authors:  Gunjan L Shah; Jaap Jan Boelens; Dean Carlow; Andrew Lin; Ryan Schofield; Nancy Cruz Sitner; Anna Alperovich; Josel Ruiz; Anthony Proli; Parastoo Dahi; Roni Tamari; Sergio A Giralt; Michael Scordo; Rick Admiraal
Journal:  Clin Pharmacokinet       Date:  2021-12-02       Impact factor: 5.577

2.  Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.

Authors:  Parastoo B Dahi; Andrew Lin; Michael Scordo; Jessica R Flynn; Sean M Devlin; Josel D Ruiz; Lauren DeRespiris; Dean Carlow; Christina Cho; Oscar B Lahoud; Miguel-Angel Perales; Craig S Sauter; Jan Jaap Boelens; Rick Admiraal; Sergio A Giralt; Gunjan L Shah
Journal:  Transplant Cell Ther       Date:  2022-05-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.